---
title: "Emergent BioSolutions Inc. (EBS.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/EBS.US.md"
symbol: "EBS.US"
name: "Emergent BioSolutions Inc."
industry: "Biotechnology"
datetime: "2026-05-19T20:26:57.402Z"
locales:
  - [en](https://longbridge.com/en/quote/EBS.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/EBS.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/EBS.US.md)
---

# Emergent BioSolutions Inc. (EBS.US)

## Company Overview

Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States, Canada, and internationally. It operates through Commercial Products, MCM Products, and All Other Revenues segments. The company offers ACAM2000, a smallpox and mpox vaccine; Anthrax Immune Globulin Intravenous (ANTHRASIL), a polyclonal antibody therapeutic for the treatment of inhalational anthrax; Botulism Antitoxin Heptavalent (BAT), an equine plasma antitoxin for the treatment of symptomatic botulism; BioThrax, an anthrax vaccine; CYFENDUS, a vaccine for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; Ebanga, a monoclonal antibody for the treatment of infection caused by Orthoebolavirus zairense; Raxibacumab injection, a monoclonal antibody therapeutic for the treatment and prophylaxis of inhalational anthrax due to Bacillus anthracis; TEMBEXA, an oral antiviral for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; and CNJ-016, a polyclonal antibody therapeutic to address complications from smallpox vaccination. It also provides NARCAN and KLOXXADO nasal sprays for the emergency treatment of known or suspected opioid overdose.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [www.emergentbiosolutions.com](https://www.emergentbiosolutions.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: D
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-19T04:30:12.000Z

**Overall: D (0.68)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 239 / 386 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: D

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -29.89% |  |
| Net Profit YoY | 93.47% |  |
| P/B Ratio | 0.80 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 419477886.48 |  |
| Revenue | 676800000.00 |  |

#### Multi Score Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -1.60% | D |
| Profit Margin | -1.27% | D |
| Gross Margin | 47.21% | B |
| Revenue YoY | -29.89% | E |
| Net Profit YoY | 93.47% | A |
| Total Assets YoY | -7.41% | E |
| Net Assets YoY | -5.36% | D |
| Cash Flow Margin | -1720.93% | E |
| OCF YoY | -29.89% | E |
| Turnover | 0.49 | C |
| Gearing Ratio | 60.38% | D |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Emergent BioSolutions Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-29.89%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "93.47%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "0.80",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "419477886.48",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "676800000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "D",
      "indicators": [
        {
          "name": "ROE",
          "value": "-1.60%",
          "rating": "D"
        },
        {
          "name": "Profit Margin",
          "value": "-1.27%",
          "rating": "D"
        },
        {
          "name": "Gross Margin",
          "value": "47.21%",
          "rating": "B"
        },
        {
          "name": "Revenue YoY",
          "value": "-29.89%",
          "rating": "E"
        },
        {
          "name": "Net Profit YoY",
          "value": "93.47%",
          "rating": "A"
        },
        {
          "name": "Total Assets YoY",
          "value": "-7.41%",
          "rating": "E"
        },
        {
          "name": "Net Assets YoY",
          "value": "-5.36%",
          "rating": "D"
        },
        {
          "name": "Cash Flow Margin",
          "value": "-1720.93%",
          "rating": "E"
        },
        {
          "name": "OCF YoY",
          "value": "-29.89%",
          "rating": "E"
        },
        {
          "name": "Turnover",
          "value": "0.49",
          "rating": "C"
        },
        {
          "name": "Gearing Ratio",
          "value": "60.38%",
          "rating": "D"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -48.78 | 537/386 | 8.27 | 7.63 | 3.50 |
| PB | 0.80 | 74/386 | 0.99 | 0.86 | 0.72 |
| PS (TTM) | 0.62 | 11/386 | 0.73 | 0.58 | 0.41 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Kiniksa Pharmaceuticals (KNSA.US) | B | A | A | B | A | A |
| 02 | Arbutus Pharma (ABUS.US) | A | A | A | A | B | A |
| 03 | Rigel Pharma (RIGL.US) | A | A | B | A | B | A |
| 04 | Spero Therap (SPRO.US) | A | A | B | A | B | A |
| 05 | CapForce Inc. (CFOR.US) | B | A | A | A | B | A |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-04T04:00:00.000Z

Total Analysts: **2**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 2 | 100% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 8.06 |
| Highest Target | 12.00 |
| Lowest Target | 12.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/EBS.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/EBS.US/norm.md)
- [Related News](https://longbridge.com/en/quote/EBS.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/EBS.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**